| scholarly article | Q13442814 |
| P2093 | author name string | M S Berger | |
| Y Hirose | |||
| R O Pieper | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | temozolomide | Q425088 |
| glioblastoma | Q282142 | ||
| P304 | page(s) | 1957-1963 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells | |
| P478 | volume | 61 |
| Q37744772 | 1,2:5,6-dianhydrogalactitol inhibits human glioma cell growth in vivo and in vitro by arresting the cell cycle at G2/M phase. |
| Q42052679 | 53BP1 is a haploinsufficient tumor suppressor and protects cells from radiation response in glioma |
| Q38715704 | 99mTc-Tetrofosmin Uptake Correlates with the Sensitivity of Glioblastoma Cell Lines to Temozolomide |
| Q30412393 | A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival |
| Q35088396 | A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme |
| Q34400848 | Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain |
| Q36401854 | Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma |
| Q52644558 | An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective. |
| Q38261426 | Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM. |
| Q42237770 | Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence |
| Q38953684 | Asiatic acid induces endoplasmic reticulum stress and apoptotic death in glioblastoma multiforme cells both in vitro and in vivo |
| Q47104641 | Autophagy flux inhibition, G2/M cell cycle arrest and apoptosis induction by ubenimex in glioma cell lines |
| Q91792626 | BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening |
| Q39156092 | Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner. |
| Q36483749 | Broad targeting of resistance to apoptosis in cancer. |
| Q38947387 | Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. |
| Q35521316 | Chemoresistance of glioblastoma cancer stem cells--much more complex than expected |
| Q38405744 | Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair |
| Q39354541 | Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma |
| Q37321206 | Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest. |
| Q45332658 | Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma. |
| Q45399501 | Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials. |
| Q36723763 | DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases |
| Q39869690 | Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide |
| Q47133357 | Dormant glioblastoma cells acquire stem cell characteristics and are differentially affected by Temozolomide and AT101 treatment |
| Q33368246 | Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies |
| Q48240259 | EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest. |
| Q37536711 | ER stress in temozolomide-treated glioblastomas interferes with DNA repair and induces apoptosis |
| Q28487714 | Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage |
| Q48145832 | Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma |
| Q39305165 | Effect of temozolomide on the U-118 glioma cell line |
| Q40257600 | Effect of temozolomide on the viability of musculoskeletal sarcoma cells |
| Q35078800 | Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells |
| Q39356631 | Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines |
| Q34566631 | Elevated DNA damage response in pancreatic cancer |
| Q39462647 | Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts |
| Q90473187 | Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1 |
| Q33733121 | Escape of U251 glioma cells from temozolomide-induced senescence was modulated by CDK1/survivin signaling |
| Q34395707 | Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies |
| Q50050008 | FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells. |
| Q34243615 | FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors. |
| Q38868168 | Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines |
| Q39434704 | Functional roles of the Ca2+-activated K+ channel, KCa3.1, in brain tumors |
| Q41460271 | GADD45A plays a protective role against temozolomide treatment in glioblastoma cells. |
| Q48969607 | Gastrin-Releasing Peptide Receptor Knockdown Induces Senescence in Glioblastoma Cells. |
| Q37684236 | Genetic and epigenetic stability of oligodendrogliomas at recurrence |
| Q90053127 | Genome-Wide CRISPR-Cas9 Screening Identifies NF-κB/E2F6 Responsible for EGFRvIII-Associated Temozolomide Resistance in Glioblastoma |
| Q59134092 | Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier |
| Q90380770 | Glypican-1 in human glioblastoma: implications in tumorigenesis and chemotherapy |
| Q42758535 | In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma |
| Q46727514 | Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin |
| Q37580300 | Increasing sensitivity to DNA damage is a potential driver for human ovarian cancer |
| Q36604113 | Inducible, reversible, and stable RNA interference in mammalian cells |
| Q34354462 | Influence of cell cycle checkpoints and p53 function on the toxicity of temozolomide in human pancreatic cancer cells |
| Q39444447 | Inhibition of NF- κ B by Dehydroxymethylepoxyquinomicin Suppresses Invasion and Synergistically Potentiates Temozolomide and γ -Radiation Cytotoxicity in Glioblastoma Cells |
| Q36701435 | Inhibition of Na(+)-K(+)-2Cl(-) cotransporter isoform 1 accelerates temozolomide-mediated apoptosis in glioblastoma cancer cells |
| Q39839523 | Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells |
| Q41630032 | Integrins and p53 pathways in glioblastoma resistance to temozolomide |
| Q37327602 | KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. |
| Q41693287 | Lysophosphatidic acid prevents apoptosis of Caco-2 colon cancer cells via activation of mitogen-activated protein kinase and phosphorylation of Bad. |
| Q40288535 | MDDD, a 4,9-diazapyrenium derivative, is selectively toxic to glioma cells by inducing growth arrest at G0/G1 independently of p53. |
| Q35096110 | MJ-66 induces malignant glioma cells G2/M phase arrest and mitotic catastrophe through regulation of cyclin B1/Cdk1 complex |
| Q39297355 | Metabolic Reprogramming in Glioma. |
| Q39308847 | Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide |
| Q39128804 | MicroRNA-125b inhibitor sensitizes human primary glioblastoma cells to chemotherapeutic drug temozolomide on invasion |
| Q39359970 | MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide |
| Q35920638 | Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide |
| Q54935991 | Modeling treatment-dependent glioma growth including a dormant tumor cell subpopulation. |
| Q38374300 | Modulations in the Peripheral Immune System of Glioblastoma Patient Is Connected to Therapy and Tumor Progression-A Case Report from the IMMO-GLIO-01 Trial |
| Q34135404 | Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance |
| Q36552658 | NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug |
| Q41575088 | Necroptosis is associated with low procaspase-8 and active RIPK1 and -3 in human glioma cells |
| Q37262177 | Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22. |
| Q33740026 | Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc |
| Q37716625 | PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas |
| Q33387317 | Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme |
| Q64946837 | Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing Radiation. |
| Q57153312 | Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma |
| Q36288249 | Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma |
| Q61442985 | Progesterone Treatment Attenuates Glycolytic Metabolism and Induces Senescence in Glioblastoma |
| Q48511550 | Prognostic significance of concomitant radiotherapy in newly diagnosed glioblastoma multiforme: a multivariate analysis of 116 patients |
| Q33382176 | Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status |
| Q36687919 | Propolis changes the anticancer activity of temozolomide in U87MG human glioblastoma cell line |
| Q34042498 | Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines. |
| Q37582420 | RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy. |
| Q43286608 | Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study |
| Q45854100 | Regiospecific Synthesis of Ring A Fused Withaferin A Isoxazoline Analogues: Induction of Premature Senescence by W-2b in Proliferating Cancer Cells |
| Q37580498 | Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype |
| Q34632817 | Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells |
| Q36723302 | Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins |
| Q28541765 | Retracted: Enhanced Anti-Tumor Effect of Zoledronic Acid Combined with Temozolomide against Human Malignant Glioma Cell Expressing O6-Methylguanine DNA Methyltransferase |
| Q47811682 | Screening critical genes associated with malignant glioma using bioinformatics analysis |
| Q28068732 | Small molecule compounds that induce cellular senescence |
| Q38762744 | Sulfasalazine intensifies temozolomide cytotoxicity in human glioblastoma cells |
| Q37761935 | Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics |
| Q37730943 | Targeted Nanotechnology in Glioblastoma Multiforme. |
| Q37928916 | Targeted brain tumor treatment-current perspectives |
| Q37960389 | Targeting DNA repair and the cell cycle in glioblastoma |
| Q28550138 | Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression |
| Q90040743 | Temozolomide and Other Alkylating Agents in Glioblastoma Therapy |
| Q42560730 | Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids |
| Q36611497 | Temozolomide induces senescence but not apoptosis in human melanoma cells. |
| Q37454341 | Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. |
| Q99414141 | Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma |
| Q46255359 | The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells |
| Q38884854 | The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment |
| Q37138573 | The FHA and BRCT domains recognize ADP-ribosylation during DNA damage response |
| Q38712286 | The Glycoside Oleandrin Reduces Glioma Growth with Direct and Indirect Effects on Tumor Cells. |
| Q37564463 | The HIV-derived protein Vpr52-96 has anti-glioma activity in vitro and in vivo. |
| Q38255481 | The future of glioblastoma therapy: synergism of standard of care and immunotherapy |
| Q38981224 | The interruption of PKC-ι signaling and TRAIL combination therapy against glioblastoma cells |
| Q37056618 | The p38 Mitogen-Activated Protein Kinase Pathway Links the DNA Mismatch Repair System to the G2 Checkpoint and to Resistance to Chemotherapeutic DNA-Methylating Agents |
| Q36651893 | Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas |
| Q45044001 | miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. |
Search more.